Replimune Group (NASDAQ:REPL) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research note released on Monday, Benzinga reports. HC Wainwright currently has a $17.00 price target on the stock.

Several other equities research analysts have also weighed in on REPL. Roth Mkm began coverage on Replimune Group in a research report on Tuesday, August 27th. They set a buy rating and a $17.00 target price on the stock. JPMorgan Chase & Co. cut their target price on Replimune Group from $17.00 to $14.00 and set an overweight rating on the stock in a research report on Tuesday, August 13th. Barclays raised their target price on Replimune Group from $13.00 to $17.00 and gave the stock an overweight rating in a research report on Friday, June 7th. Roth Capital raised Replimune Group to a strong-buy rating in a research report on Tuesday, August 27th. Finally, Wedbush reissued an outperform rating and set a $16.00 target price on shares of Replimune Group in a research report on Thursday, June 6th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of Buy and an average price target of $16.20.

Replimune Group Price Performance

REPL stock opened at $11.08 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The firm has a market capitalization of $680.48 million, a P/E ratio of -3.42 and a beta of 1.22. The business’s 50-day moving average is $10.24 and its two-hundred day moving average is $8.40. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.93.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Analysts anticipate that Replimune Group will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quest Partners LLC grew its stake in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares during the last quarter. Algert Global LLC grew its stake in shares of Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after purchasing an additional 4,340 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Replimune Group by 72.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after purchasing an additional 4,975 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in shares of Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after purchasing an additional 5,410 shares during the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.